The Clinical Core provides both services and expertise and has a strong training component for cystic fibrosis (CF) research. The services focus on regulatory support, and study design and conduct support. We serve as a local, National and International resource to collaborators for advanced clinical trial design and conduct, biostatistical and epidemiologic methods and comparative effect research methods including cost-effectiveness analysis. The Core supports the central aims of the UW Cystic Fibrosis Research and Translation Center (CFRTC): to use highly effective modulator therapy (HEMT) initiation to discover novel aspects of cystic fibrosis (CF) pathophysiology, define the clinical manifestations and best treatment approaches for the ?new? disease that CF will become, and perform basic and translational research on disease aspects that persist despite HEMT. Further, the CC fosters collaboration across the CFRTC biomedical cores to enhance translational research through the sharing of existing and development of expanded human and bacterial repositories linked to clinical databases that enable development of improved assays and clinical outcome measures. We are well positioned to continue to advance novel therapeutics through the drug development pipeline and transition to major studies in CF that focus on improving our understanding of the disease in the setting of advancing therapeutics ? specifically HEMT that will forever change the clinical landscape in CF.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
2P30DK089507-11
Application #
9982662
Study Section
Special Emphasis Panel (ZDK1)
Project Start
2010-08-07
Project End
2025-05-31
Budget Start
2020-08-15
Budget End
2021-05-31
Support Year
11
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Seattle Children's Hospital
Department
Type
DUNS #
048682157
City
Seattle
State
WA
Country
United States
Zip Code
98105
Klose, Alexander D; Paragas, Neal (2018) Automated quantification of bioluminescence images. Nat Commun 9:4262
Roch, Melanie; Varela, Maria Celeste; Taglialegna, Agustina et al. (2018) Activity of Telavancin against Staphylococcus aureus Isolates, Including Those with Decreased Susceptibility to Ceftaroline, from Cystic Fibrosis Patients. Antimicrob Agents Chemother 62:
Quon, Bradley S; Sykes, Jenna; Stanojevic, Sanja et al. (2018) Clinical characteristics of cystic fibrosis patients prior to lung transplantation: An international comparison between Canada and the United States. Clin Transplant 32:e13188
West, Natalie E; Goss, Christopher H; Nichols, David P (2018) The Long and the Short of It in Cystic Fibrosis Clinical Research Outcomes. Ann Am Thorac Soc 15:430-431
Kopp, B T; Joseloff, E; Goetz, D et al. (2018) Urinary metabolomics reveals unique metabolic signatures in infants with cystic fibrosis. J Cyst Fibros :
Bricio-Moreno, Laura; Sheridan, Victoria H; Goodhead, Ian et al. (2018) Evolutionary trade-offs associated with loss of PmrB function in host-adapted Pseudomonas aeruginosa. Nat Commun 9:2635
Crull, Matthew R; Somayaji, Ranjani; Ramos, Kathleen J et al. (2018) Changing Rates of Chronic Pseudomonas aeruginosa Infections in Cystic Fibrosis: A Population-Based Cohort Study. Clin Infect Dis 67:1089-1095
Heltshe, Sonya L; Rowe, Steven M; Skalland, Michelle et al. (2018) Ivacaftor-treated Patients with Cystic Fibrosis Derive Long-Term Benefit Despite No Short-Term Clinical Improvement. Am J Respir Crit Care Med 197:1483-1486
Kang, Inkyung; Chang, Mary Y; Wight, Thomas N et al. (2018) Proteoglycans as Immunomodulators of the Innate Immune Response to Lung Infection. J Histochem Cytochem 66:241-259
Guimbellot, Jennifer; Solomon, George M; Baines, Arthur et al. (2018) Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutations. J Cyst Fibros :

Showing the most recent 10 out of 222 publications